A DVANCES IN I NFLAMMATORY B OWEL D ISEASE presented by The Foundation for Clinical Research in Inflammatory Bowel Disease .

AADVANCESDVANCES ININ

IINFLAMMATORYNFLAMMATORY

BBOWELOWEL DDISEASEISEASE

presented by

The Foundation for Clinical Research in Inflammatory Bowel Disease

www.clinicalresearchinibd.org

2004




presented by



2004




presented by



2004

Inflammatory Bowel Disease (IBD) vs.

Irritable Bowel Syndrome (IBS)

• IBD = Inflammatory Bowel Disease– Chronic intestinal inflammation – Crohn’s disease, Ulcerative Colitis

• IBS = Irritable Bowel Syndrome– No tissue abnormality

• Change in bowel habits– Diarrhea/ Constipation/ Alternating bowel patterns

• Pain relieved with bowel movement• Increased sensitivity to intestinal motility

IBD: Overview

• Total number of cases– More than 1 million cases estimated in

United States– Ulcerative Colitis: 50%– Crohn’s disease: 50%

• Number of new cases annually– 10 new cases per 100,000 people per year– Peak onset occurs between ages of 10 and 19– Young children: 2%

IBD: Overview

• Scope of the disorder (United States)– 700,000 physician visits per year– 100,000 hospitalizations per year

• Long-term outlook– Chronic, lifelong disease without medical cures– Surgery for 50% to 80% of Crohn’s disease patients – Surgery for 20% of Ulcerative Colitis patients

• Most patients live normal, productive lives!

UCUC CDCD

Indeterminate colitis

The Spectrum of IBD

Inflammatory Bowel DiseaseGeographic Distribution

Ulcerative Colitis and Crohn’s DiseaseSame Distribution

High Incidence

Moderate Incidence

Unknown

Potential Causes of IBD

Genetics ImmuneSystem

Environment

Do All Causes Contribute Equally?

Genetics ImmuneSystem

Environment

GeneticsImmuneSystem

Genetics

Environment

Environment

ImmuneSystem

Evidence for Genetic Susceptibility to IBD

• Racial and ethnic risks of IBD

• Multiple family members with IBD

• Patterns of IBD in identical vs. fraternal twins

Genetic Susceptibility: Twin Studies

Disease Presence in Twins

Identical Fraternal twins (%) twins (%)

UC 6.3 0

CD 58 3.9

Genetic Susceptibility: Twin Studies

Disease Presence in Twins

Identical Fraternal twins (%) twins (%)

UC 6.3 0

CD 58 3.9

Searching for IBD Genes

• Candidate Gene Approach– Based on “hunch”– Investment low, likelihood

of success low

• Genome Wide Screen– Better in families with

multiply members affected– Looking for evidence of “linkage”

Searching for IBD Genes

• Candidate Gene Approach– Based on “hunch”– Investment low, likelihood

of success low

• Genome Wide Screen– Better in families with

multiply members affected– Looking for evidence of “linkage”

NOD2 is first Gene associated with Crohn’s disease

• Located at chromosome 16q12

• Similar to plant disease resistance proteins

• Related to immune response to bacteria

• Activates “down-stream” inflammatorycell-signals

1 28 124 220 273 577577 744 1044LRRCARD CARD NBD

Significance of NOD2 Risk to Developing Crohn’s disease

• One copy of Mutated Gene– 1.5-4.0 fold risk

• Two Copies: 15-40 fold risk – 10% of CD patients carry two copies– 28% of CD patients carry one copy– Actual disease presence with one or

two gene copies is less than 10%

Environmental Triggers

IBD

Antibiotics

Diet

Smoking

Infections

NSAIDs

Stress

Environmental Triggers

IBD

Antibiotics

Diet

Smoking

Infections

NSAIDs

Stress

Smoking in IBD

• Ulcerative Colitis– Smoking can protect against UC– Ex-smokers are more likely to develop UC

• Crohn’s disease– Twofold risk in current smokers– Smokers are less responsive to treatment– Smokers are more likely to develop recurrence

of disease after surgery

Environmentaltriggers

(infection, bacteria)

ModeratelyInflamed gut

Failure to control inflammation

Chronic uncontrolledinflammation = Crohn’s disease

Successful control of

inflammation

Normal gutControlled inflammation

Normal gutControlled inflammation

Genetic predisposition

What Causes IBD?

How IBD is Diagnosed

• Clinical history

• Physical examination

• Laboratory tests

• Endoscopy (Gastroscopy/Colonoscopy)

• X-ray findings

• Tissue biopsy (pathology)






• X-ray findings







• X-ray findings


Colonoscopy in IBD

• Diagnosis of IBD (UC vs. CD)– Allows visualization of large intestine

and ileum– Allows biopsies to examine colon tissue

• Determines activity of disease

• Important for pre-cancer surveillance in UC and CD

Colonoscopy in IBD

• Diagnosis of IBD (UC vs. CD)– Allows visualization of large intestine

and ileum– Allows biopsies to examine colon tissue

• Determines activity of disease

• Important for pre-cancer surveillance in UC and CD

Colonoscopy

• Requires complete “cleansing” of colon to allow visualization of bowel lining

• Preparations include:– Golytely®/Colyte® purge

• Requires drinking 1 gallon of solution

– Fleets prep®

• Small volume of purge, large volume of water

– Visicol® tablets

GastrointestinaI Tract

Stomach

Colon

Small Intestine(duodenum, jejunum, ileum)

Esophagus

Ileocecal Valve

GastrointestinaI Tract

Stomach

Colon

Small Intestine(duodenum, jejunum, ileum)

Esophagus

Ileocecal Valve

Ulcerative Colitis: Clinical

Features

Ulcerative Colitis

Left-sided ColitisProctitis Total Colitis

The small intestine is not involved.

Symptoms of Ulcerative Colitis

• Symptoms depend on extent and severity of inflammation– Rectal bleeding and urgency to evacuate– Diarrhea– Abdominal cramping– Extraintestinal (systemic) symptoms

• Joint pain/swelling• Eye inflammation• Skin lesions

Ulcerative Colitis:Colonoscopy Appearance

MildNormal Severe

Ulcerative ColitisColonic Complications

Perforation

Stricture

Bleeding

Cancer

Ulcerative ColitisColonic Complications

Perforation

Stricture

Bleeding

Cancer

Crohn’s Disease:Distribution

Upper GI

Ileocolic(most common)

Colon

Small Intestine

Common Symptoms of Crohn’s Disease

• Diarrhea

• Abdominal pain and tenderness

• Loss of appetite and weight

• Fever

• Fatigue

• Rectal bleeding and anal ulcers

• Stunted growth in children

Common Symptoms of Crohn’s Disease

• Diarrhea

• Abdominal pain and tenderness

• Loss of appetite and weight

• Fever

• Fatigue

• Rectal bleeding and anal ulcers

• Stunted growth in children

Crohn’s Disease:Colonoscopic Appearance

CobblestoneDiscrete Ulcer Stricture(Narrowing)

Perforation

Stricture

Cancer

Fistula

Abscess

Crohn’s Disease:Intestinal Complications

Crohn’s Disease:Clinical Features

PeritonitisMesenteric Abscess

Crohn’s Disease:Clinical Features

Internal Fistulae

Peri-Anal Fistulaeand/or Abscesses

External Fistula(via appendectomy incision)

Crohn’s Disease: Clinical Features

Fistula

Skin Tag

Abscess

Fissure

Crohn’s Disease:Perianal Problems

IBD: Extra-intestinal Manifestations

SkinEye

Bones and JointsKidneyLiver/

Gall Bladder

IBD: Extra-intestinal Manifestations

SkinEye

Bones and JointsKidneyLiver/

Gall Bladder

IBD:Skin Lesions

Erythema nodosum

Pyoderma gangrenosum

Treatment ofInflammatory Bowel Disease

Surgery

EmotionalSupport

Nutrition

Medications

IBD:Management Goals

Relievesymptoms

Treat inflammation

Treatcomplications

Address psychosocial

issues

Identify dysplasiaand detect

cancerImprove daily

functioning

Replenish nutritional

deficits

Minimize treatment toxicity

Maintain remission

EstablishDiagnosisEstablishDiagnosis

What Patients Should Expect

• Prior to diagnosis– Quick access/referral from Primary Care to

Specialist (Gastroenterologist)

• At diagnosis– Thoughtful explanation of disease with

opportunity for discussion


• Long-term follow-up– Continuity of care

• Primary Care Physician (if confident)• Gastroenterologist should be available

– Consideration of quality of life– Acknowledgement of problems– Access to second opinions– Maintain dignity!


• Hospital management– Knowledgeable MD/nursing staff– Willingness to refer to specialist center– Communication with patients/families– Encouragement of self-management– Choice in medical/surgical therapies– Access to dietitians, social workers

Medical Therapies for Inflammatory Bowel Disease

• 5-ASA agents– Asacol®

– Azulfidine®

– Colazal®

– Dipentum®

– Pentasa® – Rowasa® Enema– Canasa® Suppository


• Antibiotics– Cipro®

– Flagyl®

• Steroids– ACTH– Medrol®

– Prednisone– Cortenema®

– Cortifoam®


• Immunologic agents– Imuran® (Azathioprine)– Purinethol® (6-MP) – Neoral® (Cyclosporine)– Methotrexate

• Biologic agents– Remicade® (Infliximab)

5-ASA agents (Aminosalicylates)

• Induce remissions in mild-moderate – UC/CD

• Maintain remissions in mild-moderate UC

• Maintain remissions in CD after:– Medical treatment– Surgical resections

5-ASA agents(Aminosalicylates)

Benefits

• Well-tolerated

• Few side effects

• Relatively inexpensive

• Oral or Rectal

• Safe for all ages & pregnancy

Risks

• Rare allergies/side effects

• Not helpful in severe disease

• Not helpful after steroids (particularly CD)

Stomach

Small Intestine

Large Intestine

Mesalamine in microgranules

Pentasa®

Mesalaminew/

eudragit-S

Asacol®

Azo bond

Azulfidine®

Dipentum®

Colazal®

5-ASA Release Sites

Rowasa®

Canasa®

Rationale for Topical Therapy5-ASA or Steroids

• Treats the inflammation directly

• Best initial choice for active ulcerative proctitis

Corticosteriods

• Prednisone, Hydrocortisone, Medrol®, Decadron®, Cortenema®, Cortifoam®, ACTH

• Administered by pill, IV or enema

• Induce remissions in UC and CD

• No maintenance benefits

Corticosteriods

Benefits

• Induces remissions in UC and CD

• Quick fix

• Inexpensive

• Oral or rectal

Risks• No long-term benefits• Numerous side effects

– Cushingoid changes– Hypertension– Diabetes– Osteoporosis– Acne– Cataracts– Depression– Growth retardation

Antibiotics

• Flagyl® (Metronidazole), Cipro® (Ciprofloxacin, Ampicillin, etc.)

• Treats mild symptoms of Crohn’s disease– Active disease when colon is involved– Peri-anal fistulae

• Intravenous to treat severe colitis or infections such as abscess

Antibiotics

Benefits

• Mild-moderate CD

• Fistula and peri-anal CD

• Reduce recurrence after surgery (?)

Risks

• Not effective in UC

• Flagyl® (Metronidazole)– Neuropathy– Coated tongue– Yeast infections

• Cipro® (Ciprofloxacin)– Yeast infections– Tendon injury

Immune-Modulators Imuran® (azathioprine) & Purinetheol® (6-MP)

• Long-term (maintenance) treatments for UC or CD– Can treat fistulas in CD over long-term

• Primarily for patients unable to get off steroids

• Requires continuous monitoring of blood counts


Benefits

• “Steroid-sparing” in UC and CD

• Long-term maintenance

• Relatively inexpensive

Risks

• Can lower blood counts and “immunity”– Small risk of infections

• Requires long-term monitoring

• Occasional allergies– Pancreatitis– Fever


Myths

• Dangerous drugs used to treat cancer

• Cause cancer

• Should not be used longer than 3 years

• If they don’t work over 3-6 months, they will not work

• Must be stopped before or during pregnancy

Facts

• Do not cause cancer

• Can be used for more than 3 years

• If they don’t seem to work at first, the dose needs to be reassessed

• Can be used during pregnancy,

– Must be monitored

Cyclosporine

Benefits

• Effective in severe UC

• Effective in Crohn’s disease?

• Works rapidly

Risks

• Kidney damage

• Increased infection, tumors,?

Methotrexate

• Used for many decades in Rheumatoid Arthritis

• Useful in Crohn’s disease to reduce steroids

• More effective given as injection once a week

• Common side effects– Nausea, flu-like symptoms day of injection

• Rare side effects– Liver disease and Pneumonia

• Cannot be used if attempting pregnancy!!!

Biologic Therapy: Remicade® (infliximab)

• Blocks the immune system reaction that causes inflammation

• Rapidly relieves symptoms

• Allows discontinuation of steroids without recurrence of symptoms

• Can be given repeatedly over time to maintain remission

Biologic Therapy: Remicade® (infliximab)Benefits

• Induces and maintains remissions in CD

• Rapidly relieves symptoms & fistula drainage

• Steroid-sparing

• Effective even whenother therapiesfail

Risks

• Allergic reactions to intravenous infusions

• Development of antibodies and loss of response

• Reactivation of TB and other rare infections

• Expensive

How is Remicade® administered?

• Intravenous infusion

• Allergic infusion reactions: 20% of patients– Usually manageable – Often preventable with

repeated infusions

• Discontinuation of therapy due to infusion reactions is rare

Weighing the Benefits and Risks of Treatment

Potential BenefitsPotential Risks

• Control inflammation

• Improve symptoms

• Improve quality of life

• Prevent relapse

• Reduce complications

• Reduce surgery

• Short-term side effects

• Long-term toxicity

• Cost

Managing Nutrition in IBD• Malnutrition can occur in IBD

– Decreased intake of food• Symptoms• Overly zealous restriction

– Decreased absorption of nutrients• Active disease, small intestine

– Increased needs for calories and protein

• Professional nutritional assessment

• Tailor diet to individual needs & preferences

• Dietary supplements

Managing Nutrition in IBD• Malnutrition can occur in IBD

– Decreased intake of food• Symptoms• Overly zealous restriction

– Decreased absorption of nutrients• Active disease, small intestine

– Increased needs for calories and protein

• Professional nutritional assessment

• Tailor diet to individual needs & preferences

• Dietary supplements

Surgery in IBD

Ulcerative Colitis

• Surgery (colectomy, removal of colon) is curative

• Colectomy & ileostomy

• Colectomy & ileo-anal anastomosis (J-pouch)

Crohn’s Disease

• Surgery does not cure

• Disease recurs after a resection– Less after an “ostomy”

• Resection of inflamed segments to treat complications or “refractory” disease

Surgery in IBD

Ulcerative Colitis

• Surgery (colectomy, removal of colon) is curative

• Colectomy & ileostomy

• Colectomy & ileo-anal anastomosis (J-pouch)

Crohn’s Disease

• Surgery does not cure

• Disease recurs after a resection– Less after an “ostomy”

• Resection of inflamed segments to treat complications or “refractory” disease

Ulcerative Colitis:Indications for Surgery

• Failure to control severe attacks or toxic megacolon

• Acute complications

• Chronic symptoms despite medical therapy

• Medication side effects without disease control

• Dysplasia or Cancer

Crohn’s Disease:Indications for Surgery

• Obstructing strictures

• Complicating fistula

• Peri-anal abscess

• Toxic megacolon

• Localized, unresponsive disease

Colorectal Cancer Risks in IBD

• Compared to general population– Risk is 20 times higher and– Occurs at lower age

• Risk is same for UC and CD according to:– How much of colon is affected– How long the disease is present– If patient has liver disease (PSC)

• Risk is may be related to severity/activity of disease

Preventing Colon Cancer in IBD• Compliance with maintenance medications

– 5-ASA agents

• Regular follow-up and surveillance colonoscopies– Every 1-2 years after 10 years– Every year after 20 years

• Colectomy (removal of colon) if:– Dysplasia (confirmed pre-cancerous changes)– Unwilling to continue surveillance examinations

Osteoporosis and IBD

• Bone (skeletal) disease characterized by low bone density (mass)

• Increased “fragility” of bone

• Susceptibility to breaks (fractures)– Particularly of spine

(vertebrae) and hip

Osteoporosis in IBD

Risk Factors• Steroid therapy

• Smoking

• Active disease – Crohn’s disease > Ulcerative Colitis

• Females – Small stature– Family history– Post-menopausal

Preventing Osteoporosis in IBD

• Check bone density (DEXA or heel scan)

• Control active disease

• Weight bearing exercise

• Supplement calcium and vitamin D (Crohn’s disease or steroids)

• Bisphosphonates if low bone density– Actonel® or Fosomax®

IBD & Pregnancy

• Fertility is normal if disease is controlled

• Fertility is reduced in active disease

• Pregnancy outcomes are normal – Low birth weight/prematurity if active disease– NO INCREASED RISK OF BIRTH DEFECTS

• Risk of active disease after delivery– Stay on maintenance medications

IBD Medications & Pregnancy

• Medications that are safe:– 5-ASA agents– Steroids

• Low risk of cleft palate

– Most antibiotics– Imuran® (Azathioprine) and Purinethol®

(6-MP)– Remicade®(Infliximab)

• MUST BE AVOIDED– Methotrexate

Research in IBD

Where are We Heading?

Genetic Research

• Identify the gene locations– Family studies– Correlate genes with clinical patterns

• Identify the gene(s)– Likely multiple– Protective genes/harmful genes

• Identify function of genes

• How to manipulate genes

Research in the Environment

• Identify bacteria capable of causing disease– Measles virus, Mycobacteria Paratuberculosis

• Identify “normal” bacteria that produce “abnormal” immune response– Bacterial-Epithelial interactions

• Identify gene-microorganism interactions– Do immune systems mistake “self” for bacteria?

Options for Environmental Causes

• Treat patient if “infected”

• Eradicate from the environment

• Immunize to prevent “infection”

Research in Surgery

• Ileo-anal pouches– Preventing, treating Pouchitis

• Minimal invasive surgery – Laparoscopy

• Prevention of post-operative recurrence– Select subgroups– 6-MP, 5-ASA, antibiotics, biologics(?)

IBD Summary

• Ulcerative Colitis and Crohn’s disease are chronic diseases requiring long-term medical therapy

• Quality of Life is impaired during flare-ups and should be normal during remissions

• Life expectancy is same as general population

• Surgery cures Ulcerative Colitis & treats complications in Crohn’s disease

Nonadherence Is Associated With Recurrence

Follow-up

Pe

rcen

tag

e o

f M

edic

atio

nR

efill

ed in

Pre

vio

us

6 M

on

ths

No Recurrence

Recurrence

Kane et al. Am J Med. 2003;114:39-41.

Adherence Decreases Risk of Relapse

0

25

50

75

100P

erce

nta

ge

of

Pat

ien

ts (

%)

Rem

ain

ing

in R

emis

sio

n

40 36 32Adherent n =Nonadherent n = 59 32 28

Adherent

Nonadherent

0 12 24Time (months) 36

Kane et al. Am J Med. 2003;114:39-41.

for more information:

www.healthtalk.com

A DVANCES IN I NFLAMMATORY B OWEL D ISEASE presented by The Foundation for Clinical Research in Inflammatory Bowel Disease .

Documents

inflammatory bowel disease

spectrum of ibd slide

ibd patterns of ibd

lifelong disease

evidence of linkage

intestinal motility

bowel patterns

ibd racial